Tarsier Pharma Ltd. (TARX)
Tarsier Pharma will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$8.00 - $10.00
Shares Offered
5,000,000
Deal Size
$45.00M
Chart not available yet
Data will show when the stock starts trading.
| Market Cap | 258.63M |
| Revenue (ttm) | n/a |
| Net Income | -5.07M +106.4% |
| EPS | -0.18 |
| Shares Out | 28.74M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About TARX
Tarsier Pharma is a late clinical stage biopharmaceutical company, focused on the development and commercialization of novel pharmaceutical therapies to address unmet need in blinding diseases of the eye with underlying inflammatory pathologies. Our dazdotuftide platform technology is a bio-inspired immunomodulator, designed to treat blinding inflammatory ocular diseases, and is currently being developed as both eye drops (TRS01) and intravitreal injections (TRS02).
Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 3
Stock Exchange NYSE
Ticker Symbol TARX
Website https://tarsierpharma.com/
Financial Performance
Financial StatementsNews
Tarsier Pharma IPO Registration Document (F-1)
Tarsier Pharma has filed to go public with an IPO on the NYSE American
7 weeks ago - SEC
Israel-based Phase 3 ocular diseases biotech Tarsier Pharma files for a $35 million US IPO
Tarsier Pharma, an Israel-based Phase 3 biotech developing steroid-free therapies for ocular diseases, filed on Tuesday with the SEC to raise up to $35 million in an initial public offering.
7 weeks ago - Renaissance Capital